Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -130.53% | -407.82% | -180.64% | -260.87% | 74.22% |
| Total Depreciation and Amortization | -26.02% | -3.99% | -7.57% | 5.85% | -4.68% |
| Total Amortization of Deferred Charges | 9.71% | 4.27% | -32.00% | -48.01% | 43.06% |
| Total Other Non-Cash Items | 12.69% | 29.28% | 3.76% | 378.05% | -63.03% |
| Change in Net Operating Assets | 96.41% | 120.63% | 50.58% | -14.43% | -250.41% |
| Cash from Operations | 79.64% | 82.64% | 22.04% | -60.52% | -136.06% |
| Capital Expenditure | 33.65% | -258.72% | 100.00% | 100.00% | 67.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -40.74% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.52% | -123.42% | -145.49% | 168.78% | 180.48% |
| Cash from Investing | -144.52% | -141.31% | -147.78% | 198.69% | 258.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -71.19% | -- | -- | 5,761.11% | 376.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,906.40% | -- |
| Cash from Financing | -89.50% | -179.69% | -48.23% | 95,350.00% | 58.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.00% | 61.27% | -23,740.98% | 261.01% | -33.38% |